

**Amendment to the Amendment in the Nature of a Substitute to H.R. 3
Offered by Rep. Arrington of Texas**

The amendment would create a Chief Pharmaceutical Negotiator at the Office of the United States Trade Representative.

Amendment to the Amendment, the Nature of a Substitute to H.R. 1
Offered by Rep. Arington of Texas

The amendment would create a Civil Pharmaceutical Negotiator at the Office of the United States Trade Representative

AMENDMENT

OFFERED BY MR. ARRINGTON OF TEXAS

Add at the end the following (and conform the table of contents accordingly):

1 **TITLE VI—MISCELLANEOUS**

2 **SEC. 601. CHIEF PHARMACEUTICAL NEGOTIATOR AT THE**

3 **OFFICE OF THE UNITED STATES TRADE REP-**

4 **RESENTATIVE.**

5 (a) IN GENERAL.—Section 141 of the Trade Act of
6 1974 (19 U.S.C. 2171) is amended—

7 (1) in subsection (b)(2)—

8 (A) by striking “and one Chief Innovation
9 and Intellectual Property Negotiator” and in-
10 serting “one Chief Innovation and Intellectual
11 Property Negotiator, and one Chief Pharma-
12 ceutical Negotiator”;

13 (B) by striking “or the Chief Innovation
14 and Intellectual Property Negotiator” and in-
15 serting “the Chief Innovation and Intellectual
16 Property Negotiator, or the Chief Pharma-
17 ceutical Negotiator”; and

18 (C) by striking “and the Chief Innovation
19 and Intellectual Property Negotiator” and in-

1 serting “the Chief Innovation and Intellectual
2 Property Negotiator, and the Chief Pharma-
3 ceutical Negotiator”; and

4 (2) in subsection (c), by adding at the end the
5 following new paragraph:

6 “(7) The principal function of the Chief Phar-
7 maceutical Negotiator shall be to conduct trade ne-
8 gotiations and to enforce trade agreements relating
9 to United States pharmaceutical products and serv-
10 ices. The Chief Pharmaceutical Negotiator shall be
11 a vigorous advocate on behalf of United States phar-
12 maceutical interests. The Chief Pharmaceutical Ne-
13 gotiator shall perform such other functions as the
14 United States Trade Representative may direct.”.

15 (b) COMPENSATION.—Section 5314 of title 5, United
16 States Code, is amended by striking “Chief Innovation
17 and Intellectual Property Negotiator, Office of the United
18 States Trade Representative.” and inserting the following:

19 “Chief Innovation and Intellectual Property Ne-
20 gotiator, Office of the United States Trade Rep-
21 resentative.

22 “Chief Pharmaceutical Negotiator, Office of the
23 United States Trade Representative.”.

24 (c) REPORT REQUIRED.—Not later than the date
25 that is one year after the appointment of the first Chief

1 Pharmaceutical Negotiator pursuant to paragraph (2) of
2 section 141(b) of the Trade Act of 1974, as amended by
3 subsection (a), and annually thereafter, the United States
4 Trade Representative shall submit to the Committee on
5 Finance of the Senate and the Committee on Ways and
6 Means of the House of Representatives a report describing
7 in detail—

8 (1) enforcement actions taken by the United
9 States Trade Representative during the one-year pe-
10 riod preceding the submission of the report to en-
11 sure the protection of United States pharmaceutical
12 products and services; and

13 (2) other actions taken by the United States
14 Trade Representative to advance United States
15 pharmaceutical products and services.



